NervGen Pharma Corp

TSXV:NGENCanadaView on OTCQB

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.

Contact Information

Headquarters

112-970 Burrard Street, Unit 1290VANCOUVER, BC, Canada V6Z 2R4

Phone

778-731-1711

Fax

604-722-5361

Executives

President, Chief Executive Officer, Director

Michael Kelly

Chief Financial Officer, Company Secretary

William Adams

Chief Medical Officer

Daniel Mikol

Director

Adam Rogers

Director

Gianni Ruffolo